ZIVO — Zivo Bioscience Balance Sheet
0.000.00%
- $70.69m
- $69.28m
- $0.16m
Annual balance sheet for Zivo Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.138 | 8.9 | 1.8 | 0.274 | 1.54 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | — | 0.004 | 0.002 |
Prepaid Expenses | |||||
Total Current Assets | 0.168 | 8.96 | 1.9 | 0.425 | 1.64 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.049 | 0.027 | 0.189 | 0.098 | 0 |
Long Term Notes Receivable | |||||
Total Assets | 0.22 | 8.99 | 2.12 | 0.556 | 1.64 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11.4 | 2.95 | 2.03 | 2.76 | 2.04 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 11.5 | 2.95 | 2.13 | 2.76 | 2.16 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -11.3 | 6.04 | -0.011 | -2.21 | -0.515 |
Total Liabilities & Shareholders' Equity | 0.22 | 8.99 | 2.12 | 0.556 | 1.64 |
Total Common Shares Outstanding |